 |
 |
NEURTURIN FAILS CLINICAL TRIALS FOR PARKINSON'S DISEASE Lancet Neurology [2010] Oct 20 [Epub ahead of print] (Marks WJ Jr, Bartus RT, Siffert J, Davis CS, Lozano A, Boulis N, Vitek J, Stacy M, Turner D, Verhagen L, Bakay R, Watts R, Guthrie B, Jankovic J, Simpson R, Tagliati M, Alterman R, Stern M, Baltuch G, Starr PA, Larson PS, Ostrem JL, Nutt J, Kieburtz K, Kordower JH, Olanow CW.) Complete abstract Neurturin was hailed by its sponsors Ceregene and the Michael J Fox Foundation as having great potential in the treatment of Parkinson's Disease, but has been found to be completely ineffective. Neurturin (CERE-120) is an experimental drug that contains the human gene for a growth factor called neurturin. It is used to deliver the neurturin gene by surgical means, directly into the brain of people with Parkinson's Disease. It was found to be worse than doing nothing, as it was as ineffective as sham surgery (doing nothing) yet still caused severe adverse events in a third of the patients. Neurturin is the same type of treatment as GDNF reference. GDNF was also previously hailed as a great breakthrough in the treatment of Parkinson's Disease. Yet all major clinical trials of GDNF and Neurturin have failed. www.viartis.net ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn